SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Spyre Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$84.72+4.82 (+6.03%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$62.25 (+277.0%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Spyre Therapeutics, Inc. reported revenue of $0 for fiscal 2025.
Revenue
$0
FY2025
Operating income
-$201.34M
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$178.92M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$201.34M
Net income
-$178.92M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months